Patents by Inventor Brendan P. Eckelman

Brendan P. Eckelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20240376198
    Abstract: Provided herein are NKp46-targeted modified IL-2 polypeptides. Uses of the polypeptides are also provided.
    Type: Application
    Filed: August 29, 2022
    Publication date: November 14, 2024
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, Brendan P. Eckelman, Rajay A. Pandit, William Crago, Florian Sulzmaier, Heather Kinkead, Nadja Kern
  • Multivalent and Multispecific DR5-Binding Fusion Proteins
    Publication number: 20240376220
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Application
    Filed: April 4, 2024
    Publication date: November 14, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • PD-1 Single Domain Antibodies and Therapeutic Compositions Thereof
    Publication number: 20240317860
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: February 28, 2024
    Publication date: September 26, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • CD33-binding polypeptides and uses thereof
    Patent number: 12084502
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: September 10, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • CLEC12a binding polypeptides and uses thereof
    Patent number: 12043667
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 23, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • OX40-binding polypeptides and uses thereof
    Patent number: 12012459
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: June 18, 2024
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
    Patent number: 11976126
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: May 7, 2024
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Serpin fusion polypeptides and methods of use thereof
    Patent number: 11965017
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: April 23, 2024
    Assignee: InhibRx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • PD-1 single domain antibodies and therapeutic compositions thereof
    Patent number: 11945869
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: April 2, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
    Publication number: 20240101704
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 28, 2024
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, John C. TIMMER
  • CD123-binding polypeptides and uses thereof
    Patent number: 11919963
    Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: March 5, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
    Patent number: 11866507
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: January 9, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
  • Multivalent and Multispecific 41BB-Binding Proteins
    Publication number: 20230416387
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 28, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • SIGLEC-8 BINDING PROTEINS AND USES THEREOF
    Publication number: 20230406925
    Abstract: Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
    Type: Application
    Filed: July 28, 2023
    Publication date: December 21, 2023
    Inventors: Tony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
  • Serpin fusion polypeptides and methods of use thereof
    Patent number: 11827691
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a (whey acidic protein) WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 28, 2023
    Assignee: InhibRx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF
    Publication number: 20230348600
    Abstract: Provided herein are binding polypeptides that specifically bind CD28. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs that bind at least CD28. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors thereof, and methods of use and uses of the provided CD28 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: January 28, 2021
    Publication date: November 2, 2023
    Applicant: Inhibrx, Inc.
    Inventors: John C. TIMMER, Rutger H. JACKSON, Katelyn M. WILLIS, William S. CRAGO, Michael D. KAPLAN, Brendan P. ECKELMAN
  • Canine PD-1-Binding Polypeptides and Uses Thereof
    Publication number: 20230331846
    Abstract: Provided herein are VHH-containing polypeptides that bind canine PD-1. In some embodiments, VHH-containing polypeptides that bind and antagonize canine PD-1 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: October 19, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Rajay Pandit, John C. Timmer, Brendan P. Eckelman, Quinn Deveraux
  • CD33-Binding Polypeptides and Uses Thereof
    Publication number: 20230312716
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: December 16, 2022
    Publication date: October 5, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
    Publication number: 20230295336
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 6, 2023
    Publication date: September 21, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
  • Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20230235005
    Abstract: Provided herein are polypeptide comprising a modified IL-2, wherein the modified IL-2 has reduced affinity for the IL-2 receptor relative to wild type IL-2. In some embodiments, polypeptides comprising a modified IL-2 that bind and agonize activated T cells are provided. Uses of the polypeptides comprising a modified IL-2 are also provided.
    Type: Application
    Filed: July 1, 2021
    Publication date: July 27, 2023
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, Florian Sulzmaier, Katelyn M. Willis, Bryan R. Becklund, Brendan P. Eckelman